[1] LI MM, LIU JP, LI JY, et al.Influencing factors of multiple drug use and anticoagulant therapy in elderly patients with non-valvular atrial fibrillation[J]. Chinese Medicine, 2019,14(1): 9-13. [2] ZHAO RH.Evaluation of the efficacy and safety of new oral anticoagulant (NOACs) in elderly patients with non-valvular atrial fibrillation[D]. Shanxi Medical University(山西医科大学), 2017. [3] KAWABATA M, GOYA M, SASAKI T, et al.Left Atrial appendage thrombi formation in japanese non-valvular atrial fibrillation patients during anticoagulation therapy-warfarin vs. direct oral anticoagulants[J]. Circ J, 2017, 81(5): 645-651. [4] PAPPAS MA, BARNES GD, VIJAN S.Personalizing bridging anticoagulation in patients with nonvalvular atrial fibrillation-a microsimulation analysis[J]. J Gen In Med, 2017, 32(4): 464-470. [5] ZHAO RH, LI XM, MA Y, et al.Evaluation of the efficacy and safety of new oral anticoagulants in elderly patients with non-valvular atrial fibrillation[J]. Chinese Medicine and Clinic, 2017, 17(6): 805-809. [6] YANG XC.Interpretation of the 2016 European college of cardiology guidelines for the Management of Atrial Fibrillation[J]. Chinese Journal of Interventional Cardiology, 2016, 24(11): 623-628. [7] MENG WC.Comparative observation on the safety of different antithrombotic drugs in elderly patients with non-valvular atrial fibrillation[J]. People's Military Doctor(人民军医), 2017, 60(7): 45-47. [8] DELLUC A, WANG T, YAP E, et al.Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH[J]. Journal of Thrombosis and Haemostasis, 2019, 17(8) : 1247-1252. [9] KANG SH, CHOI EK, HAN KD, et al.Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants-Korean nationwide population-based study[J]. Circulation, 2017, 81(8): 1158-1164. [10] HUANG J, YE YM, WANG Q, et al.Investigation on clinical characteristics and antithrombotic therapy in elderly patients with non-valvular atrial fibrillation[J]. Lingnan Journal of Cardiovascular Diseases, 2018, 24(3): 301-303, 310. [11] PROSPERI-PORTA G, SCHNELL G, COLBERT J, et al.Multiple thrombo-embolic events from a left atrial appendage occlusion device[J]. Can J Cardiol, 2018, 34(3): 342. [12] ZHANG W, WANG XB, WU YT, et al.A comparative study of benefits and risks of new oral anticoagulants in the treatment of elderly patients with non-valvular atrial fibrillation[J]. Chinese Journal of Evidence-based Cardiovascular Medicine, 2017, 9(9): 1096-1098. [13] SAGA I, MIKA L, TUIJA V, et al.Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion[J]. Europace, 2018, 20(4): 565-568. [14] CHEN L, GONG YX, ZHANG XL.A comparative study on the clinical efficacy of rivasaban and warfarin in the treatment of elderly (≥ 80 years old) patients with non-valvular atrial fibrillation[J]. Journal of practical Cardiac, Cerebrovascular and Pulmonary Vascular Diseases, 2018, 26(9): 63-66. [15] LI J, SHI J, WU WB, et al.Effect of antithrombotic therapy on cerebrovascular accident in elderly patients with non-valvular atrial fibrillation[J]. Chinese Journal of General Practitioners, 2019, 18(2): 166-169. [16] LI X, DEITELZWEIG S, KESHISHIAN A, et al.Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients[J]. Thrombosis & Haemostasis, 2017, 117(6): 1072-1082. [17] LIP GYH, AL-SAADY N, JIN J, et al.Anticoagulation control in warfarin-treated patients undergoing cardioversion of atrial fibrillation (from the edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation trial)[J]. Am J Cardiol, 2017, 120(5): 792-796. [18] LIANG CB, MA JH, LIU Y, et al.Study on the efficacy and safety of rifampicaban and dabigar in anticoagulation therapy in elderly patients with non-valvular atrial fibrillation[J]. Journal of Clinical Military Medicine, 2018, 46(5): 60-63. |